Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Top 200 Medicines Annual Report 2019: The king of medicines

Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.

Read More »

Celltrion Shares Fall After FDA Issues Warning Letter

Shares of South Korea-based Celltrion were down more than 5 percent after the company announced it received a warning letter from the U.S. Food and Drug Administration after the regulatory agency inspected a company drug manufacturing facility.

Read More »

Novartis Showcases 4 Potential Blockbusters in Its Late-Stage Pipeline

Swiss-based Novartis is showcasing four key drugs from the company’s late stage pipeline at an R&D and investor event in England.

Read More »

FDA approves Cyltezo, a biosimilar to Humira

The FDA approved Boehringer Ingelheim Pharmaceuticals’ Cyltezo, a biosimilar to Humira, in a pre-filled syringe for treating chronic inflammatory diseases.

Read More »

Special Feature – First Year After Launch: The specialties win again

Just like 2016 and the year before, specialty drugs dominate the 2017 list of top performers in the most recent first year after launch class.

Read More »

Novartis Enbrel copy delayed until at least 2018

The Novartis copy of Amgen’s blockbuster drug Enbrel will not go on sale until at least 2018 because of the U.S. company’s patent protection challenge.

Read More »

Pfizer to ship Remicade biosimilar in November

Pfizer will begin shipping its biosimilar version of J&J’s rheumatoid arthritis drug Remicade in late November 2016 at a 15% discount to current wholesale prices.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom